Editorial
The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated nonsmall cell lung cancer
Abstract
While this quote is likely apocryphal and not, as is commonly attributed, a curse of Chinese origin (1), its ironic sentiment seems apt when one considers the rapidly shifting treatment landscape for patients with brain metastases.
